Zealand Pharma Future Growth
Future criteria checks 5/6
Zealand Pharma is forecast to grow earnings and revenue by 97% and 41.2% per annum respectively while EPS is expected to grow by 103.9% per annum.
Key information
97.0%
Earnings growth rate
103.9%
EPS growth rate
Biotechs earnings growth | 30.9% |
Revenue growth rate | 41.2% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 681 | 131 | 125 | -96 | 5 |
12/31/2023 | 972 | 474 | 362 | 10 | 6 |
12/31/2022 | 132 | -897 | -790 | -767 | 6 |
9/30/2022 | 278 | -1,118 | -999 | -978 | N/A |
6/30/2022 | 288 | -1,108 | -1,083 | -1,060 | N/A |
3/31/2022 | 302 | -957 | -1,182 | -1,161 | N/A |
12/31/2021 | 293 | -1,018 | -1,234 | -1,212 | N/A |
9/30/2021 | 158 | -925 | -1,183 | -1,181 | N/A |
6/30/2021 | 161 | -1,012 | -1,085 | -1,071 | N/A |
3/31/2021 | 347 | -909 | -870 | -844 | N/A |
12/31/2020 | 353 | -847 | -714 | -689 | N/A |
9/30/2020 | 301 | -660 | -618 | -580 | N/A |
6/30/2020 | 255 | -545 | -670 | -632 | N/A |
3/31/2020 | 54 | -624 | -698 | -671 | N/A |
12/31/2019 | 41 | -572 | -433 | -409 | N/A |
9/30/2019 | 43 | -508 | -408 | -391 | N/A |
6/30/2019 | 33 | 524 | 927 | -346 | N/A |
3/31/2019 | 28 | 551 | 952 | -320 | N/A |
12/31/2018 | 38 | 581 | 810 | -461 | N/A |
9/30/2018 | 35 | 601 | 853 | -417 | N/A |
6/30/2018 | 74 | -361 | -317 | -310 | N/A |
3/31/2018 | 68 | -346 | -326 | -320 | N/A |
12/31/2017 | 136 | -274 | -286 | -279 | N/A |
9/30/2017 | 306 | -112 | -69 | -64 | N/A |
6/30/2017 | 307 | -100 | -116 | -113 | N/A |
3/31/2017 | 306 | -102 | -57 | -52 | N/A |
12/31/2016 | 231 | -157 | 38 | 41 | N/A |
9/30/2016 | 221 | -138 | -116 | -114 | N/A |
6/30/2016 | 189 | -158 | N/A | -128 | N/A |
3/31/2016 | 188 | -139 | N/A | -120 | N/A |
12/31/2015 | 188 | -114 | N/A | -225 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 22ZA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).
Earnings vs Market: 22ZA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 22ZA is expected to become profitable in the next 3 years.
Revenue vs Market: 22ZA's revenue (41.2% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 22ZA's revenue (41.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 22ZA's Return on Equity is forecast to be high in 3 years time